Assessing the quality of pharmacoeconomic studies in India: A systematic review

PharmacoEconomics

Volumn 30, Issue 9, 2012, Pages 749-762

  Desai, Pooja R ^a   Chandwani, Hitesh S ^a   Rascati, Karen L ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

decision making; pharmacoeconomics

Indexed keywords

ABDOMINAL INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIA; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIARRHEA; ESOPHAGUS ACHALASIA; GASTROENTERITIS; GERM CELL TUMOR; HEPATITIS B; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALARIA; MALNUTRITION; MEASLES; MEDICAL PROFESSION; MENTAL DISEASE; PHARMACOECONOMICS; POSTOPERATIVE NAUSEA AND VOMITING; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF HEALTH STUDIES SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESIDENTIAL AREA; REVIEW; SCABIES; STUDY DESIGN; TYPHOID FEVER; UNSTABLE ANGINA PECTORIS; UTERINE CERVIX CANCER; VISCERAL LEISHMANIASIS;

DEVELOPING COUNTRIES; ECONOMICS, PHARMACEUTICAL; HUMANS; INDIA; PUBLISHING; RESEARCH;

EID: 84864995383     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11590140-000000000-00000     Document Type: Review

References (47)

1. Ramani KV, Mavalankar D. Health system in India: Opportunities and challenges for improvement. J Health Organ Manag 2006; 20 (6): 560-572 (Pubitemid 44772424)
2. Census of India 2001. Brief analysis of the provisional results of the 2001 census [online]. Available from URL: Http:// www.pon.nic.in/open/depts/ ecostat/census/RESULTS.HTM [Accessed 2010 Sep 2]
3. Patil AV, Somasundaram KV, Goyal RC. Current health scenario in rural India. Aust J Rural Health 2002 Apr; 10: 129-135
4. Reddy KS, Shah B, Varghese C, et al. Responding to the threat of chronic diseases in India. Lancet 2005 Nov; 366: 1746-1751
5. UNICEF. Progress for children: A world fit for children statistical review, number 6, December 2007. UNICEF, 2007 [online]. Available from URL: Http://www.unicef. org/publications/files/Progress-for-Children-No-6-revised.pdf [Accessed 2012 Jun 6]
6. Patel AR, Nowalk MP. Expanding immunization coverage in rural India: A review of evidence for community health workers. Vaccine 2010 Jan; 28: 604-613
7. Gavaza P, Rascati KL, Oladapo AO, et al. The state of health economic evaluation research in Nigeria. Pharmacoeconomics 2010 Jul; 28 (7): 539-553
8. Gavaza P, Rascati K, Brown C, et al. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe. Curr Ther Res 2008 Jun; 69 (3): 268-285
9. Teerawattananon Y, Russel S, Mugford M. A systemic review of economic evaluation literature in Thailand: Are the data good enough to be used by policy makers? Pharmacoeconomics 2007; 25 (6): 467-479 (Pubitemid 46849188)
10. Lee KS, Brouwer WB, Lee SI, et al. Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information? Pharmacoeconomics 2005; 23 (7): 709-721
11. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
12. Sullivan SD, Lyles A, Luce BR, et al. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefit management organizations. J Manag Care Pharm 2001 Jul; 7 (4): 272-282
13. Offman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of economic analysis: Implications of utilizing the QHES. J Manag Care Pharm 2003 Jan; 9 (1): 53-61
14. Bender MA, Kumarasamy N, Mayer KH, et al. Costeffectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010 Feb; 50 (3): 416-425
15. Sutherland T, Meyer C, Bishai DM, et al. Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis. Int J Gynecol Obstet 2010; 108 (3): 289-294
16. Olliaro P, Darley S, Laxminarayan R, et al. Costeffectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009 Aug; 14 (8): 918-925
17. Dabral M. Cost-effectiveness of supplementary immunization for measles in India. Indian Pediatr 2009 Nov; 46 (11): 957-962
18. Cook J, Sur D, Clemens J, et al. Evaluating investments in typhoid vaccines in two slums in Kolkata, India. J Health Popul Nutr 2009 Dec; 27 (6): 711-724
19. Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009 Jan; 14 (1): 88-92
20. Rose J, Hawthorn RL, Watts B, et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: Model based analysis. BMJ 2009; 339: b3482
21. Bachewar NP, Thawani VR, Mali SN, et al. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol 2009 Feb; 41 (1): 9-14
22. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India. Int J Gynecol Obstet 2009; 104 (3): 189-193
23. George C, Yesoda A, Jayakumar B, et al. A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India. J Clin Pharm Ther 2009; 34 (1): 33-40
24. Kochhar P, Suvarna V, Duttagupta S, et al. Costeffectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting. Value Health 2008; 11 Suppl. 1: S33-8 (Pubitemid 351490456)
25. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99 (2): 230-238
26. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007 Jul; 21 Suppl. 4: S117-28 (Pubitemid 47051757)
27. Attili VS, Chandra RC, Anupama G, et al. Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors. J Cancer Res Ther 2007 Sep; 3 (3): 150-152 (Pubitemid 350293671)
28. Ramachandran A, Snehalatha C, Yamuna A, et al. Costeffectiveness of the interventions in the primary prevention of diabetes among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007 Oct; 30 (10): 2548-2552 (Pubitemid 47547791)
29. ShafiqN,Malhotra S, Pandhi P, et al.Arandomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins: Enoxaparin, nadroparin and dalteparin. The ESCAPe- END study. Pharmacology 2006; 78 (3): 136-143 (Pubitemid 44764029)
30. Sahni M, Jindal K, Abraham N, et al. Hepatitis B immunization: Cost calculation in a community-based study in India. Indian J Gastroenterol 2004 Jan; 23 (1): 16-18 (Pubitemid 38477967)
31. Anand K, Sankar R, Kapoor SK. Cost of syrup versus capsule form of vitamin A supplementation. Indian Pediatr 2004 Apr; 41 (4): 377-384 (Pubitemid 38525341)
32. Patel AB, DhanDe LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: A randomized controlled trial. Cost Eff Resour Alloc 2003; 1 (1): 7
33. Patel V, ChisholmD, Rabe-Hesketh S, et al. Efficacy and costeffectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial. Lancet 2003; 361 (9351): 33-39 (Pubitemid 36050959)
34. Aggarwal R, Ghoshal UC, Naik SR. Assessment of costeffectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003; 38 (2): 215-222 (Pubitemid 36169632)
35. Gogtay NJ, Kadam VS, Desai S, et al. A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai, India. J Assoc Physicians India 2003 Sep; 51: 877-879 (Pubitemid 41279867)
36. Ghoshal UC, Aggarwal R, Kumar S, et al. Pneumatic dilation versus intrasphincteric botulinum toxin injection in the treatment of achalasia cardia in India: An economic analysis. Indian J Gastroenterol 2002 Sep; 21 (5): 193-196
37. Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: Cost-effectiveness in developing countries. Natl Med J India 2002; 15 (6): 320-327 (Pubitemid 36113659)
38. Subramaniam B, Madan R, Sadhasivam S, et al. Dexamethasone is a cost-effective alternative to ondansetron in preventing PONV after pediatric strabismus repair. Br J Anesth 2001; 86 (1): 84-89 (Pubitemid 32014127)
39. Gogtay NJ, Desai S, Kadam VS, et al. A randomized, parallel-group study in Mumbai (Bombay), comparing chloroquine with chloroquine plus sulfadoxine-pyrimethamine in the treatment of adults with acute, uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol 2000; 94 (4): 309-312 (Pubitemid 30410172)
40. Sundar S, Gupta LB, Rastogi V, et al. Short-course, costeffective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94 (2): 200-204 (Pubitemid 30307297)
41. Awasthi S, PanDe VK, Fletcher RH. Effectiveness and costeffectiveness of albendazole in improving nutritional status of pre-school children in urban slums. Indian Pediatr 2000; 37 (1): 19-29 (Pubitemid 30058609)
42. Sundar S, Goyal AK, More DK, et al. Treatment of antimony- unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998; 92 (7): 755-764 (Pubitemid 29355489)
43. XE. Free currency charts (USA/INR) [online]. Available from URL: Http://www.xe.com/currencycharts/?from= USD&to=INR&view=10Y [Accessed 2010 Sep 5]
44. Powe NR, Griffiths RI. The clinical-economic trial: promise, problems, and challenges. Control Clin Trials 1995 Dec; 16 (6): 377-394 (Pubitemid 26035807)
45. World Health Organization. NCD country profiles, 2011 [online]. Available from URL: Http://www.who.int/nmh/ countries/ind-en.pdf [Accessed 2012 Jun 6]
46. Rascati KL. Chapter 13: International perspective. Essentials of pharmacoeconomics. Philadelphia (PA): Lippincott Williams and Wilkins, 2009
47. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. Pharmacoeconomics 1997 Jul; 12 (1): 10-16(Pubitemid 27298328)